| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC26010 | BAY-545 Featured | BAY-545 is a novel, potent and selective antagonist of A2B adenosine receptor with an IC50 of 59 nM. BAY-545 also exhibits IC50s of 66, 400, 280 nM for human, mouse, rat A2Badenosine receptor in cells, respectively. |
|
| DC12653 | BAY-598 Featured | BAY-598 is a selective inhibitor of SMYD2. |
|
| DC12088 | BAY-678 racemate | BAY-678 racemate is a chemical probe candidate for Human Neutrophil Elastase (HNE). |
|
| DC20749 | BAY-707 | BAY-707 is a highly potent, selective and substrate-competitive inhibitor of MTH1 (NUDT1) with IC50 of 2.3 nM. |
|
| DC22016 | BAY-7598 | BAY-7598 (BAY7598) is a potent, selective MMP12 inhibitor.. |
|
| DC11218 | BAY-8002 Featured | BAY-8002 is a novel potent, selective, orally available monocarboxylate transporter 1 (MCT1) inhibitor (Kd=7.9 nM). |
|
| DC22017 | BAY-826 | BAY-826 (BAY826) is a novel selective, highly potent, orally available TIE-2 inhibitor (dissociation constant=1.6 nM). |
|
| DC11505 | BAY-850 Featured | BAY-850 (BAY 850, BAY850) is a potent, isoform selective, cellularly active ATAD2 bromodomain inhibitor with binding IC50 of 166 nM in TR-FRET assay. |
|
| DC10107 | BAY-876 Featured | BAY-876 is the first highly selective GLUT1 inhibitor with IC50 of 0.002 uM. show good metabolic stability in vitro and high oral bioavailability in vivo. |
|
| DC11915 | BAY-958 | BAY-958 (BAY958, LDC526) is a potent, selective PTEFb/CDK9 inhibitor with IC50 of 5 nM against CDK9/CyclinT1. |
|
| DC10057 | Bayer-18 Featured | Bayer-18 is a selective TYK2 inhibitor, with an IC50 of 18.7nM on TYK2 as measured by TYK2 HTRF assays. |
|
| DC7854 | BAZ2-ICR | BAZ2-ICR is a selective BAZ2 bromodomain inhibitor (Kd values are 109 and 170 nM for BAZ2A and BAZ2B respectively). |
|
| DC7372 | Bazedoxifene-Acetate Featured | Bazedoxifene acetate (TSE 424; WAY-TES 424), a novel selective estrogen receptor modulator (SERM), has been developed to have favorable effects on bone and the lipid profile while minimizing stimulation of uterine or breast tissues. |
|
| DC8922 | Bazedoxifene Featured | Bazedoxifene is a selective estrogen receptor modulator (SERM) currently in development for osteoporosis prevention and treatment. |
|
| DC12280 | BB-Cl-Amidine | BB-Cl-Amidine is a peptidylarginine deminase (PAD) inhibitor. |
|
| DC10058 | BBT594 | BBT594 (NVP-BBT594), is potent and selective inhibitor of RET and JAK2. |
|
| DC20754 | BC-1215 Featured | BC-1215 (BC1215) is a highly unique, selective E3 ligase F box component Fbxo3 inhibitor with IL1β IC50 of 0.9 ug/mL. |
|
| DC20755 | BC-1485 | BC-1485 is a first-in-class, small molecule inhibitor of FIEL1 (Fibrosis-inducing E3 ligase 1) that exhibits potent activity toward disrupting FIEL1-directed PIAS4 ubiquitination. |
|
| DC21401 | BC-21 | BC-21 (NSC 109268) is a novel small molecule inhibitor that effectively inhibits the β-catenin/Tcf4 interaction with Ki of 6.55 uM. |
|
| DC20757 | BC-23 | BC-23 (NSC 45382) is a novel inhibitor of β-catenin/Tcf4 interaction with IC50 of 1.7 uM. |
|
| DC10885 | BCI-121 Featured | BCI-121 is a SMYD3 inhibitor that impairs the proliferation of cancer cell. |
|
| DC20758 | BCI-137 | BCI-137 is a chemical compound able to compete with Argonaute 2 miRNAs binding, binds to Ago2 with Kd of 126 uM. |
|
| DC12446 | BCL6 inhibitor 14 | BCL6 inhibitor 14 is a potent BCL-6 inhibitor with FRET IC50 of 63 nM.. |
|
| DC12447 | BCL6 PROTAC 15 | BCL6 PROTAC 15 is a novel B-cell lymphoma 6 (BCL6) PROTAC, significantly degrade BCL6 in a number of DLBCL cell lines, but neither BCL6 inhibition nor degradation selectively induces marked phenotypic response. |
|
| DC20760 | BCL6-IN-8 | BCL6-IN-8 (BCL6-i) is a potent, irreversible and cell-active BCL6 inhibitor with inact/KI value of 1.9 × 104 M-1 s-1, targets Cys53 located at the protein-protein interaction interface. |
|
| DC20761 | BCM-599 | BCM-599 is an efficient HBV capsid assembly inhibitor with in vitro IC50 of 13 uM, shows synergistic inhibitory effects on decreasing viral concentration combined with lamivudine in vivo.. |
|
| DC9826 | BCTC Featured | BCTC is a potent and specific inhibitor of transient receptor potential cation channel subfamily M member 8 (TRPM8) in prostate cancer (PCa) DU145 cells. |
|
| DC23980 | BCX-1470 | BCX-1470 (BCX1470) is a serine protease inhibitor that inhibits the esterolytic activity of factor D (IC50=96 nM) and C1s (IC50=1.6 nM). |
|
| DC8313 | BD1047.2HBr Featured | BD 1047 dihydrobromide is a selective antagonist of σ receptors. |
|
| DC23499 | BD-1047 Featured | BD-1047 is a potent, selecitve Sigma 1 receptor (σ1) antagonist with Ki of 0.93 nM. |
|
